Scientific Publications by FDA Staff

Clin Chem 2015 Nov;61(11):1391-8

Demonstration of the pre-Emergency Use Authorization path using 3 minor groove binder-hydrolysis probe assays to detect Escherichia coli O104:H4.

Hartman LJ, Heinrich ML, Zovanyi AM, Ingram MF, Hobson JP, Kulesh DA, Craw PD, Jaissle JG, Norwood DA, Minogue TD

BACKGROUND: The Department of Defense (DoD) and the Food and Drug Administration (FDA) have collaboratively worked on a pre-Emergency Use Authorization (pre-EUA) process for in vitro diagnostic (IVD) devices, using FDA's regulatory flexibilities under the EUA authorities. The pre-EUA process enables FDA review of data in anticipation of a request for an EUA, advancing US government public health emergency preparedness efforts. METHODS: The IVD device developed to detect Escherichia coli O104:H4, for which an EUA has not been issued, serves as an example to illustrate that process. Specifically, DoD designed real-time PCR assays to target the virulent E. coli strain O104:H4 (etiological agent of the 2011 German outbreak) including fliC (flagellin), Agg3C (AAF), and rfbO104 (wbwC) on the basis of the published sequences. RESULTS: After development and optimization of these 3 specific assays, a defined protocol was followed to determine and document the sensitivity and specificity of each assay analytically. CONCLUSIONS: FDA reviewed these data and returned commentary on additional required experiments to complete the pre-EUA process and expedite the use of the device should there be an emergency need for an IVD device to detect this virulent E. coli strain before such a test is cleared by FDA.